AT A GLANCE: THE MPT R&D PIPELINE

Status of products in development

		Preclinical	Phase	el	Phase II	> F	Phase III	Phase IIIb/IV
/	Implant	•••						
A	IUD	•						
UIIIIH	Long-acting injectable	••						
Ż	Oral pill							•1
	Vaginal insert	•••						
۲	Vaginal film	••						
	Vaginal gel	•					•	
NSL	Vaginal/rectal insert		•					
0	Vaginal ring		•					
HIV + Contraception		HIV + other STIs		HIV + other STIs + Contraception			Contraception + other STIs	
14		5		6			0	

¹ The dual pill product is going through bioequivalence studies in lieu of clinical trials because the drug components are already approved separately, but not in combination. Therefore, it does not follow the traditional R&D pathway.

² This product addresses both HIV and Bacterial vaginosis (BV). BV is not sexually transmitted but can be linked to sexual activity. While BV is not an STI, it has been included here for simplicity. Adapted from: *The Initiative for MPTs (IMPT) Product Development Database; Treatment Action Group (TAG) 2023 Pipeline Report; MATRIX R&D Landscape Review 2024.*

